Screener
ARS Pharmaceuticals, Inc. SPRY Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026.
- Filed
- May 15, 2026, 6:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-225142
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total current liabilities | 49,612 | 39,145 |
| Term loans, net (including related party amounts of $4,826 and $4,819, respectively) | 96,522 | 96,374 |
| Financing liability | 74,673 | 72,140 |
| Contract liability, net of current portion | 978 | 1,130 |
| Other accrued liabilities | 4,478 | 4,605 |
| Total liabilities | 226,263 | 213,394 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity |
Item 1. Financial Statements
FAQ
- What is ARS Pharmaceuticals, Inc.'s contract liabilities?
- ARS Pharmaceuticals, Inc. (SPRY) reported contract liabilities of $978K in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s contract liabilities changed year-over-year?
- ARS Pharmaceuticals, Inc.'s contract liabilities decreased by 27.0% year-over-year, from $1.34M to $978K.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s contract liabilities?
- Over 4 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s contract liabilities has grown at a -21.6% compound annual growth rate (CAGR), from $3M to $1.13M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about ARS Pharmaceuticals, Inc.'s contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude